Compare Funko Inc (FNKO) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs GSK plc — how do they compare? Funko Inc trades at $6.44 (market cap $363.97M), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 252.4× Funko Inc's market cap, and GSK plc pays a 3.9% dividend while Funko Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and GSK plc for 93 Days on average.
| FNKO | GSK | |
|---|---|---|
Market Cap | $363.97M | $91.88B |
Volume | 1,422,651 | 7,730,529 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $61.18 |
52-Week Low | $2.81 | $43.24 |
Typical Hold Time | 33 Days | 93 Days |
Enterprise Value | $584.62M | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $6.50, up 3.01% today, with strong technical momentum showing bullish moving average signals. The company reported mixed Q2 2026 results with revenue growth of 7% to $207.7 million and significant EBITDA improvement, though net income remains negative. Analyst consensus is mixed with 42.9% buy ratings and a $7.58 price target, representing 16.6% upside potential from current levels.
Investment outlook balances improving operational metrics against persistent profitability challenges. The stock offers potential upside based on analyst targets and recent earnings beats, but risks include negative net margins, volatile cash flows, and high debt levels that could pressure shareholder returns in a competitive collectibles market.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
